Neurofibromin 2 (Merlin)

A membrane protein homologous to the ERM (Ezrin-Radixin-Moesin) family of cytoskeleton-associated proteins which regulate physical properties of membranes. Alterations in neurofibromin 2 are the cause of NEUROFIBROMATOSIS 2.

Also Known As:

Networked: 727 relevant articles (19 outcomes, 115 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Giovannini, Marco: 27 articles (11/2020 - 08/2002)
2.	Hanemann, C Oliver: 23 articles (01/2022 - 06/2003)
3.	Morrow, David A: 23 articles (01/2021 - 06/2006)
4.	Scirica, Benjamin M: 23 articles (01/2021 - 06/2006)
5.	Gutmann, David H: 22 articles (01/2014 - 05/2002)
6.	Morrison, Helen: 19 articles (01/2021 - 12/2002)
7.	Braunwald, Eugene: 16 articles (10/2015 - 06/2006)
8.	Murphy, Sabina A: 14 articles (10/2015 - 04/2007)
9.	McClatchey, Andrea I: 13 articles (01/2018 - 05/2003)
10.	Gutmann, D H: 13 articles (02/2011 - 06/2000)

Related Diseases

1.	Neoplasms (Cancer) 09/01/2010 - "Together, these recent advances have improved our basic understanding about merlin function, its regulation, and the major signaling pathways regulated by merlin and provided the foundation for future translation of these findings into the clinic for patients bearing the cancers in which merlin function and/or its downstream signaling pathways are impaired or altered." 05/05/2016 - "To clarify the relationship between Merlin(NF2) and malignant tumor will be helpful for the prevention and treatment of cancer. " 07/27/2006 - "These results link merlin to the cell cycle control machinery and may help to understand its tumor suppressor function." 01/01/2023 - "This study evaluated the relative contribution of CD44- and Merlin-dependent processes to the development and progression of liver tumors. " 10/07/2016 - "Previous studies suggest a potential functional role for the raft-cytoskeleton in the action of the putative tumor suppressors PTRF/Cavin-1 and Merlin. "
2.	Acute Coronary Syndrome 01/01/2012 - "Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial." 07/01/2009 - "Using data from the MERLIN-TIMI 36 trial, we assessed the association between the extent of angina after an acute coronary syndrome (ACS) and subsequent cardiovascular resource utilization among 5460 stable outpatients who completed the Seattle Angina Questionnaire at 4 months after an ACS and who were then followed for an additional 8 months. " 07/01/2009 - "Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial." 04/21/2009 - "Continuous ST-segment monitoring in contemporary acute coronary syndrome patients: the magic of MERLIN-TIMI 36." 04/25/2012 - "Here, we investigate how the approach of developing clinical models might be improved across three distinct patient populations (patients with acute coronary syndrome enrolled in the DISPERSE2-TIMI33 and MERLIN-TIMI36 trials, patients undergoing inpatient surgery in the National Surgical Quality Improvement Program registry, and patients undergoing percutaneous coronary intervention in the Blue Cross Blue Shield of Michigan Cardiovascular Consortium registry). "
3.	Neurilemmoma (Schwannoma) 01/01/2002 - "Using two-parameter FACS analysis we show that expression of wild-type merlin in NF2 cells led to significant reduction of proliferation and G0/G1 arrest in transduced schwannoma cells. " 12/01/2021 - "In these studies we explore the role of PAK1 and its closely related paralog, PAK2, both pharmacologically and genetically, in Merlin-deficient Schwann cells and in a genetically engineered mouse model (GEMM) that develops spontaneous vestibular and spinal schwannomas. " 10/15/2020 - "Several studies have identified Merlin as a key regulator of the Hippo, MAPK, and PI3K signaling pathways; however, definitive evidence demonstrating the importance of these pathways in schwannoma pathogenesis is absent. " 01/01/2018 - "We established an untransformed merlin-deficient human Schwann cell line for use in drug discovery studies for NF2-associated schwannomas. " 11/02/2017 - "To study the relationship between Merlin deficiency and tumourigenesis, we have developed an in vitro model comprising human primary schwannoma cells, the most common Merlin-deficient tumour and the hallmark for NF2. "
4.	Ischemia 04/01/2023 - "The primary theory for the cause of brainstem ischemia in juvenile NF2 is a microvascular cause due to deficiency of neurofibromin 2, a regulator of endothelial development. " 12/01/1998 - "Continuous ST-segment trends in leads II and V5 were recorded using Hewlett-Packard Merlin monitors postbypass until discharge from the postsurgical unit, and printouts were analyzed for episodes of ischemia. " 04/28/2009 - "Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial." 08/01/2015 - "We examined the 1-year incidence of recurrent cardiovascular (CV) events in the subgroup of patients with prior chronic angina (n = 3565) enrolled in the randomized, double-blind, placebo-controlled Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation ACS (MERLIN)-Thrombolysis In Myocardial Infarction (TIMI) 36 trial who did or did not have a PCI within 30 days of the index event. " 03/23/2010 - "We measured plasma BNP in all available baseline samples (n = 4,543) among patients with non-ST-segment elevation ACS randomized to ranolazine or placebo in the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial and followed them for a mean of 343 days. "
5.	Myocardial Infarction 08/01/2015 - "We examined the 1-year incidence of recurrent cardiovascular (CV) events in the subgroup of patients with prior chronic angina (n = 3565) enrolled in the randomized, double-blind, placebo-controlled Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation ACS (MERLIN)-Thrombolysis In Myocardial Infarction (TIMI) 36 trial who did or did not have a PCI within 30 days of the index event. " 03/23/2010 - "We measured plasma BNP in all available baseline samples (n = 4,543) among patients with non-ST-segment elevation ACS randomized to ranolazine or placebo in the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial and followed them for a mean of 343 days. " 01/01/2014 - "Ranolazine did not improve cardiovascular mortality or affect incidence of myocardial infarction in the MERLIN (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome)-TIMI (Thrombolysis In Myocardial Infarction) 36 trial, but significantly decreased the incidence of recurrent angina. " 03/01/2010 - "Extensive experimental studies and clinical evidence (Metabolic Efficiency with Ranzolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction-36 [MERLIN TIMI-36] trial) indicate potential antiarrhythmic efficacy of the antianginal agent ranolazine. " 06/01/2014 - "The MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis in Myocardial Infarction 36) trial randomized non-ST-elevation ACS patients to ranolazine or placebo, with no exclusion for renal dysfunction (except dialysis). "

Related Drugs and Biologics

1.	Ranolazine
2.	Proteins (Proteins, Gene)
3.	Phosphotransferases (Kinase)
4.	Mechanistic Target of Rapamycin Complex 1
5.	Bevacizumab (Avastin)
6.	Mitogen-Activated Protein Kinase Kinases (MEKs)
7.	tyrosine receptor (receptor, tyrosine)
8.	nutlin 3
9.	Protein Kinase Inhibitors
10.	Angiogenic Proteins

Related Therapies and Procedures

1.	Therapeutics
2.	Percutaneous Coronary Intervention
3.	Conservative Treatment
4.	Drug Therapy (Chemotherapy)
5.	Self-Help Devices (Assistive Technology)